Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schiff

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
The Journal of Rheumatology|June 2, 2004
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritisKaren E Hansen, Julie P Hildebrand, Mark C Genovese, et al.
The Journal of Rheumatology|February 17, 2006
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind studyAlyssa K Johnsen, Michael H Schiff, Philip J Mease, et al.
Annals of the Rheumatic Diseases|August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialD van der Heijde, M H Schiff, J Sieper, et al.
The Journal of Rheumatology|June 21, 2001
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritisL W Moreland, S B Cohen, S W Baumgartner, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
Arthritis and Rheumatism|June 28, 2006
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trialDésirée van der Heijde, Alan Kivitz, Michael H Schiff, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
The New England Journal of Medicine|July 17, 1997
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinL W Moreland, S W Baumgartner, M H Schiff, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The Journal of Rheumatology|June 2, 2004
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritisKaren E Hansen, Julie P Hildebrand, Mark C Genovese, et al.
The Journal of Rheumatology|February 17, 2006
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind studyAlyssa K Johnsen, Michael H Schiff, Philip J Mease, et al.
Annals of the Rheumatic Diseases|August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialD van der Heijde, M H Schiff, J Sieper, et al.
The Journal of Rheumatology|June 21, 2001
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritisL W Moreland, S B Cohen, S W Baumgartner, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
Arthritis and Rheumatism|June 28, 2006
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trialDésirée van der Heijde, Alan Kivitz, Michael H Schiff, et al.
The Journal of Rheumatology|May 17, 2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trialDésirée van der Heijde, Edward C Keystone, Jeffrey R Curtis, et al.
Current Medical Research and Opinion|January 6, 2006
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky, William R Palmer, John A Goldman, et al.
The New England Journal of Medicine|July 17, 1997
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinL W Moreland, S W Baumgartner, M H Schiff, et al.
Pageof 8